Aytu Biopharma Inc's ability to collect accounts receivable sequentially worsen to 1.86, indicating more challenging environment then in the second quarter 2026, but still, it is a far cry from any concerns. Aytu Biopharma Inc's Accounts Receivable average collection period in the Mar 31 2026 quarter, has increased to 196 days, from 193 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 294 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 1817 to 1980.

What is Receivable Turnover Ratio?
What is Aytu Biopharma Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AYTU Receivables Turnover Ratio	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter	(Mar 31 2025) III. Quarter
Y / Y Receivable Change	-31.64 %	21.73 %	43.46 %	31.92 %	19.72 %
Y / Y Revenue Change	-34.86 %	-7.36 %	-17.51 %	-14.03 %	0.64 %
Receivable Turnover Ratio (TTM)	1.86	1.89	2.01	2.28	2.54
AYTU's Total Ranking	# 1980	# 1817	# 1845	# 2930	# 1681
Accounts Receivable average collection period days	196	193	182	160	144
Seq. Receivable Change	-20.81 %	-6.93 %	6.64 %	-13.04 %	41.03 %
Seq. Revenue Change	-20.69 %	10.91 %	-18.88 %	-8.72 %	12.8 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 80
Healthcare Sector	# 295
Overall Market	# 1980

Receivable Turnover Ratio Statistics
High	Average	Low
0.74	0.37	0.07
(Jun 30 2023)		(Dec 31 2015)

AYTU Company Profile • Back to AYTU Efficiency Comparisons • Compare AYTU Receivables Turnover Ratio to its Competitors

Financial Statements
Aytu Biopharma Inc's Accounts Receivable	$ 24 Millions	Visit AYTU's Balance sheet
Aytu Biopharma Inc's Sales TTM	$ 56 Millions	Visit AYTU's Income Statement
Sources of AYTU's Revenues		Visit AYTU's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
AYTU's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
AYTU's Growth Rates	AYTU's Roa	AYTU's Inventory Turnover Ratio	AYTU's Dividend Comparisons
AYTU's Profitability Ratios	AYTU's Roi	AYTU's Asset Turnover Ratio	AYTU's Dividend Growth
AYTU's Valuation Ratios	AYTU's Roe	AYTU's Financial Strength Ratios	AYTU's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Select Medical Holdings Corp	6.22	$ 5,521.134 Millions	$ 887.240 Millions
Emergent Biosolutions Inc	6.22	$ 676.800 Millions	$ 108.775 Millions
Adm Tronics Unlimited Inc	6.22	$ 3.347 Millions	$ 0.538 Millions
Harvard Bioscience Inc	6.22	$ 84.970 Millions	$ 13.665 Millions
Neogen Corporation	6.21	$ 871.509 Millions	$ 140.236 Millions
Lakeland Industries Inc	6.20	$ 193.318 Millions	$ 31.179 Millions
Vertex Pharmaceuticals Inc	6.20	$ 12,218.000 Millions	$ 1,972.200 Millions
Heartflow Inc	6.19	$ 189.487 Millions	$ 30.604 Millions
Zoetis Inc	6.16	$ 9,509.000 Millions	$ 1,544.250 Millions
Pacira Biosciences inc	6.13	$ 734.864 Millions	$ 119.835 Millions
Labcorp Holdings Inc	6.11	$ 14,144.200 Millions	$ 2,313.275 Millions
Keros Therapeutics Inc	6.11	$ 42.450 Millions	$ 6.944 Millions
Star Equity Holdings Inc	6.11	$ 178.521 Millions	$ 29.202 Millions
Novavax inc	6.11	$ 596.338 Millions	$ 97.582 Millions
Treace Medical Concepts Inc	6.11	$ 207.318 Millions	$ 33.951 Millions
Ispecimen inc	6.09	$ 1.027 Millions	$ 0.169 Millions
Gilead Sciences Inc	6.09	$ 29,736.000 Millions	$ 4,882.500 Millions
Pacific Health Care Organization Inc	6.09	$ 6.394 Millions	$ 1.051 Millions
Picard Medical Inc	6.05	$ 5.160 Millions	$ 0.853 Millions
Integra Lifesciences Holdings Corp	6.04	$ 1,644.510 Millions	$ 272.482 Millions
Accuray Incorporated	6.00	$ 427.893 Millions	$ 71.334 Millions
Bio techne Corp	5.96	$ 1,210.490 Millions	$ 203.053 Millions
Infusystem Holdings Inc	5.95	$ 142.404 Millions	$ 23.918 Millions
Macrogenics Inc	5.95	$ 157.083 Millions	$ 26.390 Millions
Avantor Inc	5.95	$ 6,552.200 Millions	$ 1,101.625 Millions
Anaptysbio Inc	5.93	$ 232.388 Millions	$ 39.175 Millions
Msa Safety Inc	5.92	$ 1,917.299 Millions	$ 323.658 Millions
Maxcyte inc	5.92	$ 32.287 Millions	$ 5.452 Millions
Cadre Holdings inc	5.92	$ 635.663 Millions	$ 107.363 Millions
Stereotaxis Inc	5.90	$ 30.801 Millions	$ 5.219 Millions

Date modified: 2026-08-29T17:22:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.